Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D011024 | Pneumonia, Viral NIH | 0.17 |
D011014 | Pneumonia NIH | 0.08 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is an open label clinical study to evaluate the activity of chloroquine phosphate in patients with SARS-CoV-2 virus infection. The study aims to document possible prevention of pneumonia in patients staying at home and in improving the symptoms of SARS-CoV-2 pneumonia in patients who will be hospitalised.
Description: Achieving 50% reduction in symptom score for patients with lower respiratory tract infection on day 8 visit from study initiation.
Measure: 50% reduction in symptom score for patients with lower respiratory tract infection Time: Day 8 visit from study initiationDescription: Lack of progression to lower respiratory tract infection in patients enrolled in the study due to upper respiratory tract infection on day 8 visit from study initiation.
Measure: Lack of progression for patients with upper respiratory tract infection Time: Day 8 visit from study initiationDescription: Lower respiratory tract infection rating takes place. The symptoms checked are: Cough, Chest pain, Dyspnea, expectoration. For each symptom score is given from 0 to 3 depending on the intensity and they are summed.
Measure: Comparison of the primary endpoint with respective patients not receiving the treatment Time: Day 14 visit from study initiationDescription: It is defined as the presence of both of the following: Respiratory quotient (pO2 / FiO2) less than 150 Need for treatment with CPAP or mechanical ventilation
Measure: Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment. Time: Day 14 visit from study initiationDescription: Frequency of AEs and SAEs
Measure: Frequency of AEs and SAEs Time: Day 14 visit from study initiation